CytoDyn Inc. will present updated clinical data from its ongoing Phase 2 CLOVER study evaluating leronlimab combined with TAS-102 and bevacizumab in metastatic colorectal cancer (mCRC) at the ESMO Congress 2026 in Madrid. The presentation will provide new insights into the role of the CCR5 receptor in colorectal cancer and support further development of leronlimab for difficult-to-treat cancers. This data is expected to advance understanding of the drug's potential and inform future treatment strategies.
CytoDyn's updated clinical data presentation coincides with a broad downturn in the health sector on Pluang, where only 29 of 128 US health stocks rose as of Oct 08, 2026 18:43 WIB. For readers following health stocks, here is Pluang's market snapshot: DNA (Ginkgo Bioworks Holdings Inc) traded at USD 11.07 with a 3.49% decline and a typical hold time of 7 days, MESO (Mesoblast Limited) at USD 13.48 down 3.30% with a 14-day hold, and SANA (Sana Biotechnology Inc) at USD 2.80 up 2.94% with a 23-day hold and 73% buy order activity.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
